A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the safety and efficacy of Myfortic with CellCept
in liver transplant patients. Myfortic and CellCept are both immunosuppressive
(anti-rejection) drugs. CellCept is commonly used after liver transplantation but
gastrointestinal (GI) side effects are very common, sometimes necessitating in its
discontinuation. Myfortic is a new drug similar to CellCept, except it is enteric-coated. Our
hypothesis is that Myfortic has less GI side effects than CellCept and also has comparable
effectiveness to CellCept.